Ardsley Advisory Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Ardsley Advisory Partners’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2,500	Closed	-$286K	–	211
2020 Q3	$286K	Buy	+2,500	New	+$270K	0.06%	112
2019 Q4	–	Sell	-2,500	Closed	-$245K	–	206
2019 Q3	$245K	Sell	2,500 -2,500	-50%	-$282K	0.05%	113
2019 Q2	$653K	Buy	5,000 +1,500	+43%	+$193K	0.1%	83
2019 Q1	$473K	Buy	+3,500	New	+$435K	0.09%	83
2018 Q4	–	Sell	-114,000	Closed	-$15.8M	–	179
2018 Q3	$15.8M	Sell	114,000 -13,000	-10%	-$1.63M	2.14%	17
2018 Q2	$15.8M	Sell	127,000 -20,000	-14%	-$2.34M	2.37%	11
2018 Q1	$16.4M	Sell	147,000 -37,000	-20%	-$4.42M	2.46%	13
2017 Q4	$22M	Buy	184,000 +12,500	+7%	+$1.52M	2.67%	7
2017 Q3	$24.1M	Sell	171,500 -5,000	-3%	-$679K	3.2%	5
2017 Q2	$21.5M	Buy	176,500 +174,500	+8,725%	+$20.3M	3.34%	5
2017 Q1	$242K	Buy	+2,000	New	+$258K	0.04%	127

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Ardsley Advisory Partners's ALXN Position: Q4 2020 in Review

Ardsley Advisory Partners sold out of Alexion Pharmaceuticals (ALXN) in Q4 2020, closing a stake of 2,500 shares — an estimated $286K sold.

Ardsley Advisory Partners first reported a position in ALXN in Q1 2017 and held it in 11 quarters. The position peaked at $24.1M in Q3 2017. 827 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.

Ardsley Advisory Partners reported no remaining Alexion Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Ardsley Advisory Partners sold 2,500 Alexion Pharmaceuticals shares in Q4 2020, an estimated $286K.
Ardsley Advisory Partners first reported a position in Alexion Pharmaceuticals in Q1 2017 and held it in 11 quarters.
Ardsley Advisory Partners's Alexion Pharmaceuticals position peaked at $24.1M in Q3 2017.
827 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.

Based on Ardsley Advisory Partners's 13F filing for Q4 2020, filed 16 Feb 2021.